?? Exciting News in Cancer Treatment: FDA Grants Accelerated Approval to Bristol Myers Squibb's Breyanzi for Follicular Lymphoma Patients

I'm thrilled to share that the US Food and Drug Administration has granted accelerated approval to Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) as a groundbreaking therapy for previously treated relapsed or refractory follicular lymphoma patients.

This significant milestone follows the successful Phase II TRANSCEND-FL clinical trial, where Breyanzi demonstrated remarkable results. Among 94 efficacy-evaluable patients, the therapy achieved an impressive overall response rate of 95.7 percent after a median follow-up of 16.8 months. Notably, the median duration of response was not yet reached at the time of data cutoff, indicating the potential for long-lasting benefits.

Breyanzi's approval for this patient population is based on its effectiveness in follicular lymphoma patients who had received at least two prior lines of treatment, including an anti-CD20 antibody and an alkylating agent.

This approval expands Breyanzi's existing footprint in the US, Japan, and Europe, where it is already approved as a second- or later-line treatment for certain large B-cell lymphoma patients. Additionally, it is approved in several countries, including the US, Japan, Europe, Switzerland, the UK, and Canada, for treating relapsed and refractory large B-cell lymphoma.

The accelerated approval of Breyanzi marks a significant advancement in the treatment landscape for follicular lymphoma patients, offering hope and improved outcomes for those who have exhausted other treatment options. This achievement underscores Bristol Myers Squibb's commitment to developing innovative therapies that address unmet medical needs.

I'm excited about the potential impact of Breyanzi and look forward to witnessing its continued contribution to improving the lives of patients with follicular lymphoma. This news is a testament to the ongoing progress in cancer treatment and reinforces our collective dedication to advancing patient care. #Breyanzi #CancerTreatment #FDAApproval #FollicularLymphomaTreatment #BristolMyersSquibb